Dr Reddy's Laboratories posted a 3.76 per cent decline in net profit at Rs 156.1 crore for the fourth quarter ended March 31, 2009, as compared to Rs 162.2 crore in the corresponding period a year ago.

Total income increased by 12.36 per cent to Rs 1,166.5 crore for the quarter under review as against Rs 1,038.1 crore.

According to a press release, the company recorded an impairment loss with respect to intangible assets related to its acquired German subsidiary Betapharm, amounting to Rs 316.7 crore (euro 47 million), before tax and with respect to goodwill of Rs 1,085.6 crore (euro 162 million). This is a one-time non-cash charge in the income statement and incorporates the provisions of applicable accounting standards.

Total income for the fiscal year increased by 34.73 per cent to Rs 7,000 crore from Rs 5,195.4 crore recorded in previous year. The growth in revenues was driven by the successful launch of the authorized generic version of GlaxoSmithKline’s Imitrex (Sumatriptan Succinate), in late November 2008 and by the key markets of North America and Russia. Excluding revenues from Sumatriptan, the year-on-year growth is at 24 per cent.

The company said revenues from global generics business is at Rs 4,980 crore ($979 million) in FY09 as against Rs 3,300 crore ($649 million) in FY08, with a year-on-year growth of 51 per cent. Revenues from pharmaceutical services and active ingredients (PSAI) increased by 13 per cent to Rs 1,880 crore ($369 million) in FY09 as compared with Rs 1,660 crore ($327 million) in FY08.

During the year, the company launched 116 new generic products, filed 110 new generic product registrations and filed 55 DMFs globally.

The company has also recommended a final dividend of Rs 6.25 (125 per cent) per equity share of Rs 5 face value, subject to the approval of shareholders.

New Ipad Application :Business Standard's all new IPad App Click here to download for free Other Stories      - Wall Street up on Greece, but gains seen limited - FII-TO-FII: Pantaloon traded at 7% premium - Civic polls: Saffron alliance retains Mumbai, Thane - MCX awaits trading rules in commodity options, indices - Govt to provide incentives for electronic chip manufacturing

Tags : Dr Reddy's | Q4FY09 | net profit | net loss | consolidated results | pharma   Read Business news in  Advertisements -  Now property search gets more exciting than ever before! -  High Growth Business Opportunities in Africa - Register to explore -  Earn fuel worth Rs.2400 with Citi -  India's No. 1 Property Site. Click here to know more.. -  Diseases earlier, Saving Costs, Extending Lives. Know More.. -  Get 5% cashback on telephone bills with Citi -  Enjoy the journey as much as the destination. click to know more.. -  Exim Bank Conclave on India - Africa Project Partnership. Know more.. -  Medium-sized businesses are the engines of a smarter planet. -  Creating Wealth made simple the SIP way. Know more.. -  Only Developer to give a guarantee on time space & rate. -  Office 365 for professionals and small businesses. -  Buy Your Property with Our Triple Guarantee in India. -  Improve Patient Care & Experience. Click here to know more -  Win a Business Class Ticket to Europe..Know more.. -   Introduce a New Automotive Luxury Car.. know more